Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Study Identifier
PCYC-0212
CT.gov Identifier
NCT00120939
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Lung Cancer - Non-Small Cell Lung Cancer (NSCLC)
  • Gastrointestinal Cancer - General
    • Study Drug
  • Motexafin Gadolinium
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * At least 18 years old * Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme * ECOG performance status score either 0, 1, or 2 * Willing and able to provide written informed consent
    Exclusion Criteria:
    * Greater than two prior cytotoxic regimens * Laboratory values showing adequate function of bone marrow, liver, and kidneys * Uncontrolled hypertension * Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80

    Protocol Summary

    The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.

    Study Locations

    Location
    Status
    Location
    University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States, 15213
    Status
    Not applicable